Private Wealth Partners LLC lifted its holdings in Zoetis Inc (NYSE:ZTS) by 6.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 115,536 shares of the company’s stock after acquiring an additional 7,110 shares during the quarter. Zoetis accounts for about 2.0% of Private Wealth Partners LLC’s holdings, making the stock its 16th biggest holding. Private Wealth Partners LLC’s holdings in Zoetis were worth $13,112,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its stake in shares of Zoetis by 2.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after acquiring an additional 39,319 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Zoetis by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock valued at $531,801,000 after acquiring an additional 785,088 shares during the last quarter. CWM LLC raised its stake in shares of Zoetis by 107.9% during the first quarter. CWM LLC now owns 813 shares of the company’s stock valued at $82,000 after acquiring an additional 422 shares during the last quarter. Sonata Capital Group Inc. bought a new position in shares of Zoetis during the first quarter valued at $232,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Zoetis during the first quarter valued at $1,140,000. Institutional investors own 90.42% of the company’s stock.
Shares of ZTS traded down $1.26 during trading hours on Thursday, hitting $126.38. 66,744 shares of the stock were exchanged, compared to its average volume of 1,904,989. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $128.41. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. The business has a 50-day moving average of $117.83 and a 200-day moving average of $105.05. The firm has a market capitalization of $60.93 billion, a P/E ratio of 40.40, a price-to-earnings-growth ratio of 3.20 and a beta of 0.92.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same period in the prior year, the company posted $0.77 earnings per share. Zoetis’s revenue for the quarter was up 9.3% compared to the same quarter last year. As a group, analysts forecast that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on ZTS shares. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and raised their price target for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. SunTrust Banks raised their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday, August 13th. Craig Hallum raised their price target on shares of Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Gabelli downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target for the company. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Finally, Barclays raised their price target on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average target price of $115.13.
In other Zoetis news, Director Willie M. Reed sold 1,900 shares of the firm’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $110.58, for a total value of $210,102.00. Following the completion of the sale, the director now directly owns 2,816 shares in the company, valued at $311,393.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the completion of the sale, the executive vice president now owns 48,877 shares of the company’s stock, valued at $6,022,623.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,432 shares of company stock valued at $5,083,246. 0.29% of the stock is currently owned by corporate insiders.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.